Becker's Healthcare January 3, 2024
Rylee Wilson

Medicare Advantage beneficiaries are more likely to be prescribed biosimilar drugs than their counterparts in traditional Medicare, a study published Dec. 28 in JAMA Health Forum found.

The study, conducted by researchers at the FDA, CMS and policy research firm Acumen, compared biosimilar uptake for seven categories of drugs among MA and traditional Medicare populations. In six of the seven categories, biosimilar uptake was higher among MA beneficiaries.

Biosimilars, highly similar replications...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Insurance, Medicare Advantage, Patient / Consumer, Pharma / Biotech, Provider, Survey / Study, Trends
Related Articles:
Moderna says it’s ‘one step closer’ to a norovirus vaccine as the virus spreads across the U.S.
Report: Prices for top Medicare Part D drugs nearly doubled since entering the market
High cost of weight loss drugs drives employers to require nutrition counseling, in boost for startups
Announcement: Andreessen Horowitz Partners with Lilly to Launch First-of-Its-Kind Biotech Ecosystem Fund
Boosting biopharma R&D performance with a next-generation technology stack

Share This Article